Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100, for Acute Respiratory Distress Syndrome (ARDS) and COVID-19 Patients ANN ARBOR, Mich., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Asalyxa Bio, a new spinout from the University of Michigan focused on severe neutrophil-mediated diseases, today announced its formation and seed...